Aaron Fletcher Biography and Net Worth

Director of Actuate Therapeutics

Dr. Fletcher founded and serves as CEO of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. Bios Research provides fundamental healthcare industry research focused in the biotech and med-tech sub-sectors and through this research Dr. Fletcher has a strong understanding of commercial viability in the marketplace. Dr. Fletcher holds a PhD in Biochemistry from Colorado State University, and serves as a professor at Dallas Baptist University where he teaches Biochemistry, Bioethics, and Cell Biology. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over 10 years.

How do I contact Aaron G.L. Fletcher?: The corporate mailing address for Dr. Fletcher and other Actuate Therapeutics executives is 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107. Actuate Therapeutics can also be reached via phone at (847) 986-4190 and via email at [email protected]. Learn More on Aaron G.L. Fletcher's contact information.
Has Aaron G.L. Fletcher been buying or selling shares of Actuate Therapeutics?: Aaron G.L. Fletcher has not been actively trading shares of Actuate Therapeutics within the last three months. Learn More on Aaron G.L. Fletcher's trading history.
Are insiders buying or selling shares of Actuate Therapeutics?: In the last twelve months, insiders at the sold shares 1 times. They sold a total of 280,000 shares worth more than $1,624,000.00. The most recent insider tranaction occured on January, 5th when Director Todd S Thomson sold 280,000 shares worth more than $1,624,000.00. Insiders at Actuate Therapeutics own 58.0% of the company. Learn More about insider trades at Actuate Therapeutics.
Information on this page was last updated on 1/5/2026.

Aaron G.L. Fletcher Insider Trading History at Actuate Therapeutics

Aaron G.L. Fletcher Buying and Selling Activity at Actuate Therapeutics

Actuate Therapeutics Company Overview

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Today's Range

Now: $0.89

$0.77

$0.96

50 Day Range

MA: $1.13

$0.62

$1.78

2 Week Range

Now: $0.89

$0.60

$8.49

Volume

460,167 shs

Average Volume

213,631 shs

Market Capitalization

$21.25 million

P/E Ratio

N/A

Dividend Yield